Duloxetine Pregnancy and Breastfeeding Warnings
Duloxetine is also known as: Cymbalta
Duloxetine Pregnancy Warnings
The physician may wish to consider tapering duloxetine in the third trimester.
Duloxetine has been assigned to pregnancy category C by the FDA. Neonates exposed to SSRIs and SNRIs late in the third trimester have developed complications requiring prolonged hospitalization, respiratory support, and tube feeding. (Such complications can arise immediately upon delivery.) Reported clinical findings have included respiratory distress, cyanosis, apnea, seizures, temperature instability, feeding difficulty, vomiting, hypoglycemia, hypotonia, hypertonia, hyperreflexia, tremor, jitteriness, irritability, and constant crying. (These features are consistent with either a direct toxic effect of SSRIs and SNRIs, or possibly a drug discontinuation syndrome.) In some cases, the clinical picture is consistent with serotonin syndrome. Animal studies on duloxetine have revealed evidence of adverse effects on embryo/fetal and postnatal development. There are no controlled data in human pregnancy. Duloxetine should be given during pregnancy and particularly during the third trimester, only if the potential benefits outweigh the potential risks to the fetus.
Duloxetine Breastfeeding Warnings
Duloxetine is excreted into human milk. The effects in the nursing infant are unknown. According to the manufacturer, breast-feeding is not recommended during administration of duloxetine. Lilly maintains a pregnancy registry to monitor the pregnancy outcomes of women exposed to Cymbalta while pregnant. Healthcare providers are encouraged to register any patient who is exposed to Cymbalta during pregnancy by calling the Cymbalta Pregnancy Registry at 1-866-814-6975 or by visiting www.cymbaltapregnancyregistry.com
In lactating women receiving duloxetine, the daily infant dose, on a mg per kg basis, is estimated at approximately 0.14% of the maternal dose. Duloxetine and/or its metabolites are excreted into the milk of lactating rats.
- Duloxetine use while Breastfeeding (in more detail)
- duloxetine delayed-release capsules Consumer Information
- Pregnancy Support Group
- FDA Pregnancy Categories
- Medicine use during Pregnancy
- Medicine use while Breastfeeding
- Safe Medications during Breastfeeding
Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This drug information does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.